Abstract
The quaternary ammonium compound N,N′-dodecyl-bispicolinium dibromide (bPiDDB) potently and selectively inhibits nicotinic receptors (nAChRs) mediating nicotine-evoked [3H]dopamine release and decreases nicotine self-administration, suggesting that this polar, charged molecule penetrates the blood-brain barrier (BBB). This report focuses on 1) BBB penetration of bPiDDB; 2) the mechanism of permeation; and 3) comparison of bPiDDB to the cations choline and N-octylnicotinium iodide (NONI), both of which are polar, charged molecules that undergo facilitated BBB transport. The BBB permeation of [3H]choline, [3H]NONI, and [14C]bPiDDB was evaluated using in situ rat brain perfusion methods. Cerebrovascular permeability surface-area product (PS) values for [3H]choline, [3H]NONI, and [14C]bPiDDB were comparable (1.33 ± 0.1, 1.64 ± 0.15, and 1.3 ± 0.3 ml/s/g, respectively). To ascertain whether penetration was saturable, unlabeled substrate was added to the perfusion fluid. Unlabeled choline (500 μM) reduced the PS of [3H]choline to 0.15 ± 0.06 μl/s/g (p < 0.01). Likewise, unlabeled bPiDDB (500 μM) reduced the PS of [14C]bPiDDB to 0.046 ± 0.005 μl/s/g (p < 0.01), whereas unlabeled NONI reduced the PS for [3H]NONI by approximately 50% to 0.73 ± 0.31 μl/s/g. The PS of [14C]bPiDDB was reduced (p < 0.05) in the presence of 500 μM choline, indicating that the BBB choline transporter may be responsible for the transport of bPiDDB into brain. Saturable kinetic parameters for [14C]bPiDDB were similar to those for [3H]choline. The current results suggest that bPiDDB uses the BBB choline transporter for ∼90% of its permeation into brain, and they demonstrate the carrier-mediated BBB penetration of a novel bisquaternary ammonium nAChR antagonist.
Footnotes
-
This study was supported by National Institutes of Health Grant U19DA17548 (to L.P.D., P.A.C., D.D.A., and P.R.L.).
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.107.130906.
-
ABBREVIATIONS: nAChR, nicotinic acetylcholine receptor; MLA, methyllycaconitine; BBB, blood-brain barrier; bPiDDB, N,N′-dodecyl-bispicolinium dibromide; CNS, central nervous system; NONI, N-octylnicotinium iodide; PS, permeability product(s); HPLC, reverse phase-high-performance liquid chromatography; Vd, volume of distribution.
- Received August 27, 2007.
- Accepted October 2, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|